Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor medications, commonly referred to as statins, are among the most widely prescribed medications. Variation in individual response to statins concerning low-density lipoprotein cholesterol reduction, clinical event benefit, and side effects has been observed. Some of this variability is attributed to demographic and environmental issues, chief of which is compliance. A large portion of the individual response to statin therapy is attributed to single nucleotide polymorphisms that have recently been elucidated, several of which seem to have clinical utility.
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Cholesterol, LDL / metabolism
-
Drug Resistance / genetics*
-
Dyslipidemias / drug therapy*
-
Dyslipidemias / metabolism
-
Forecasting
-
Gene-Environment Interaction
-
Humans
-
Hydroxymethylglutaryl CoA Reductases / genetics*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / pharmacokinetics
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
-
Lipid Metabolism / genetics*
-
Patient Compliance
-
Pharmacogenetics
-
Polymorphism, Single Nucleotide / drug effects
-
Precision Medicine* / methods
-
Precision Medicine* / trends
Substances
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hydroxymethylglutaryl CoA Reductases